EP MedSystems Receives Market Clearance
from FDA for Constant Voltage EP-4 Stimulator

WEST BERLIN, N.J.--(BUSINESS WIRE)--Sept. 20, 2004--EP MedSystems, Inc. (NASDAQ: EPMD - News), a market leader in electrophysiology (EP) products used to diagnose and treat certain types of cardiac rhythm disorders, announced today that it had received market clearance from the FDA for an enhancement to its EP-4 Computerized Cardiac Stimulator allowing the physician to stimulate the heart using either constant current or constant voltage output. The enhanced stimulator now can be used in both EP diagnostic studies of the heart and pacemaker implantations where measuring voltage thresholds are fundamental. The stimulator is integrated with the Company's EP-WorkMate® Electrophysiology Workstation, as well as other diagnostic technologies used in the monitoring and diagnosis of arrhythmias in the heart.

EP MedSystems' President & CEO Reinhard Schmidt commented: "This market clearance is an exciting milestone in our commitment to develop and deliver a state of the art product suite. As the only stimulator with FDA clearance capable of both constant voltage and constant current output, this opens a significant new market opportunity. This clearance gives us a competitive advantage over other EP stimulator manufacturers, who currently only offer constant current stimulators, and further reinforces EP MedSystems' position as a market leader in meeting the demanding needs of EP Physicians by offering a multi-functional, streamlined, and cost efficient product line. We see this approval contributing to our continued accelerated revenue growth for the balance of this year."

About EP MedSystems:
EP MedSystems develops and markets cardiac electrophysiology ("EP") products used to diagnose and treat certain cardiac rhythm disorders. The Company's EP product line includes the EP-WorkMate® Electrophysiology Workstation with RPM(TM) Real-time Position Management(TM) navigation technology, the EP-4(TM) Computerized Cardiac Stimulator, fixed and deflectable diagnostic electrophysiology catheters and related disposable supplies, the ALERT® System and ALERT family of internal cardioversion catheters, and the ViewMate® intracardiac ultrasound catheter imaging. For more information, visit our Website at www.epmedsystems.com.

Forward Looking Statements:
This Release may contain certain statements of a forward-looking nature relating to future events or the future financial performance of the Company. Forward-looking statements include information concerning our possible or assumed future results of operations and statements preceded by, followed by or including the words "believes", "expects", "anticipates", "intends", "plans", "estimates", "see opportunities" or similar expressions. Such forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such forward-looking statements are only predictions and are subject to risks and uncertainties that could cause actual results or events to differ materially and adversely from the events discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, EP MedSystems' history of losses, uncertainty of market acceptance of our products and level of sales, uncertainty of future profitability and future liquidity needs, possible costs, fines or penalties that may be incurred in connection with government inquiries and investigations and risks regarding regulatory approvals and demand for new and existing products, as stated in the Company's Annual Report filed on Form 10-KSB and quarterly reports filed on Form 10-Q and 10-QSB.

EP MedSystems cautions investors and others to review the cautionary statements set forth in this press release and in EP MedSystems' reports filed with the Securities and Exchange Commission and cautions that other factors may prove to be important in affecting the EP MedSystems' business and results of operations. Readers are cautioned not to place undue reliance on this press release and other forward-looking statements, which speak only as of the date of this release. EP MedSystems undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events.

For Further Information Contact:

EP MedSystems, Inc.
Matthew C. Hill
(856)753-8533

Investor Relations Firm:
MKR Group, LLC
Charles Messman, Todd Kehrli
(818)556-3700